Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 01, 2020 16:05 ET | Source: Recro Pharma, Inc.

Recro Announces Change in Location of its 2020 Annual Meeting of Shareholders to its Corporate Headquarters

MALVERN, Pa., May 01, 2020 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH) (the “Company”), a high-performing, revenue generating contract development and manufacturing organization, today...
March 04, 2020 07:00 ET | Source: Recro Pharma, Inc.

Recro Reports Financial Results for the Year Ended 2019

Recro Completes Separation of Baudax Bio and Is Now a Pure Play CDMO Business Company Sets Annual Revenue Record; 2019 Revenues of $99.2 Million Company to Host Conference Call Today at 8:00 AM ET ...
March 02, 2020 07:00 ET | Source: Recro Pharma, Inc.

Recro to Report Year End 2019 Financial Results and Host Conference Call and Webcast on March 4, 2020

MALVERN, Pa., March 02, 2020 (GLOBE NEWSWIRE) -- Recro, Inc. (NASDAQ:REPH) a leading contract development and manufacturing organization (CDMO) with integrated solutions for the development,...
November 21, 2019 16:30 ET | Source: Recro Pharma, Inc.

Recro Completes Separation of Baudax Bio and Becomes a Dedicated Contract Development and Manufacturing Organization

Recro Capitalizing on Strong and Growing CDMO Business Business Poised to Continue Driving Revenue and Begin Generating Profits Recro Will Continue to Trade on NASDAQ Under Ticker Symbol “REPH” ...
November 21, 2019 07:00 ET | Source: Recro Pharma, Inc.; Baudax Bio, Inc.

Baudax Bio™ Launches as a New Pharmaceutical Company Aimed at Advancing Promising, Non-Opioid Analgesic Therapies

Company Launches with $19 Million in Funding and Rights to IV Meloxicam, Along with Other Clinical-Stage Pipeline Assets Trading of “BXRX” Begins Tomorrow on NASDAQ MALVERN, Pa., Nov. 21, 2019 ...
November 13, 2019 07:00 ET | Source: Recro Pharma, Inc.

Recro Pharma Announces Effectiveness of Baudax Bio Form 10 Registration Statement

Separation of Baudax Bio as Independent Company Expected to be Completed With Distribution on November 21, 2019 Baudax Bio Common Stock Approved for Listing on the NASDAQ Capital Market MALVERN,...
November 08, 2019 07:00 ET | Source: Recro Pharma, Inc.

Recro Pharma Reports Third Quarter 2019 Financial Results

CDMO Business Achieves 37% Growth in 2019 Year to Date Revenues; Consolidated Company Achieves Profitability from Operations, Turns Cash Flow Positive and Raises 2019 Revenue Guidance to $98-100...
November 05, 2019 16:05 ET | Source: Recro Pharma, Inc.

Recro Pharma to Report Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 8, 2019

MALVERN, Pa., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH) today announced that it will report third quarter financial results on Friday, November 8, 2019. Recro's management...
November 05, 2019 07:00 ET | Source: Recro Pharma, Inc.

Recro Pharma’s Board of Directors Approves Separation of Acute Care Business Segment and Declares Special Dividend Distribution of Baudax Bio Common Stock

MALVERN, Pa., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a specialty pharmaceutical company with a high-performing revenue generating contract development and manufacturing...
October 31, 2019 07:00 ET | Source: Recro Pharma, Inc.

FDA Grants Appeal to Recro Pharma for IV Meloxicam New Drug Application

Received Positive Response from FDA Regarding IV Meloxicam Formal Dispute Resolution Request Company Remains on Track to Execute Spin Out of Acute Care Business Segment During the Fourth Quarter of...